Veru Inc. may need to conduct another study of its COVID-19 therapeutic ahead of an emergency use authorization following a negative 9 November US Food and Drug Administration advisory panel.
The Pulmonary-Allergy Drugs Advisory Committee voted 8-5 that the known and potential benefits of VERU-111 (sabizabulin) do not outweigh the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?